{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.1","upperLimit":"28.8","value":"14.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"description":"PFS was defined as the time from study entry to the first documented disease progression, or death from any cause, whichever occurs first. Disease progression was assessed by RECIST 1.1.","dispersionType":"90% Confidence Interval","groups":[{"description":"Ribociclib 600 mg administered orally daily for 21 days followed by 7 days off in 28-day treatment cycle plus Letrozole 2.5 mg administered orally daily for 28 days.","id":"OG000","title":"Ribociclib and Letrozole"}],"paramType":"MEDIAN","populationDescription":"Eligible participants who received any amount of protocol therapy","reportingStatus":"POSTED","timeFrame":"From date of protocol entry to date of first documented progression or death assessed up to approximately 55 months","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}